9:35–10:00

Abstract 5009

Nivolumab for metastatic renal   cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial.

Nivolumab治疗转移性肾细胞癌（mRCC):一项随机的关于剂量调整的II期临床研究结果。

姚  欣(Xin Yao)

Abstract 5011

Inhibition of PD-L1 by   MPDL3280A and clinical activity in pts with metastatic urothelial bladder   cancer (UBC).

MPDL3280A抑制PD-L1及其对转移性膀胱尿路上皮癌患者的临床作用。

Abstract 5012

Immunomodulatory activity of   nivolumab in previously treated and untreated metastatic renal cell carcinoma   (mRCC): Biomarker-based results from a randomized clinical trial.

Nivolumab对经治和未治转移性肾细胞癌的免疫调节活性：基于生物标志物的随机临床试验结果。

10:00–10:10

专家评述

Discussion Topic: Immunotherapy for RCC?

讨论主题：肾癌细胞免疫治疗？

王秀问(Xiu-Wen Wang)

10:10–10:15

讨论(Q &   A)

周芳坚(Fang-Jian Zhou)

谢晓冬(Xiao-Dong Xie)

王秀问(Xiu-Wen Wang)